Outlook Therapeutics price target lowered to $10 from $12 at Guggenheim
Guggenheim lowered the firm’s price target on Outlook Therapeutics (OTLK) to $10 from $12 and keeps a Buy rating on the shares following ...
Axsome Therapeutics price target raised to $195 from $135 at Guggenheim
Guggenheim raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $135 and keeps a Buy rating on the shares after updating ...
Stratos Wealth Partners LTD. Cuts Position in Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust (NYSE:GBAB)
Stratos Wealth Partners LTD. decreased its holdings in Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust (NYSE:GBAB – Free Report) by 9.5% during the 4th quarter, HoldingsChannel reports ...
Berkshire Takes Swig of Modelo Maker Constellation; Cuts BofA, Citigroup
Its beer brands include Corona and Modelo Especial, which in 2023 surpassed Bud Light as the top-selling beer in the United ...